The Discovery
The Convenience Problem
Why Good Drugs Weren't Good Enough
Key moment
Nearly half of diabetes patients stop medications within a year
By the mid-2000s, GLP-1 drugs were proving their worth. Exenatide (Byetta) lowered blood sugar and helped patients lose weight. But there was a problem: patients had to inject it twice a day, every day, right before meals.
For many people, that was just too much. Studies showed that nearly half of diabetes patients stopped taking their medications within the first year. Missed doses meant uncontrolled blood sugar, which meant kidney damage, blindness, amputations, and heart attacks down the road.
The math was brutal: a drug that works perfectly but isn't taken is worse than a mediocre drug taken every day. Pharmaceutical companies raced to create longer-lasting GLP-1 drugs. The prize was a once-weekly injection — something so convenient that patients would actually stick with it.
The Breakthrough
The Fusion Strategy
Building a Better Molecule
Key moment
59,000 Da molecule — 18 times larger than natural GLP-1
At Eli Lilly's research labs in Indianapolis, scientists tried something nobody had done before with GLP-1. Instead of just tweaking the peptide like others were doing, they fused it to something much bigger: an Fc fragment — the tail end of a human antibody.
Antibodies are the immune system's guided missiles. They're large proteins that naturally circulate in the blood for weeks before being cleared. By attaching GLP-1 to an antibody fragment, Lilly's team created a molecule that was enormous compared to natural GLP-1 — about 59,000 daltons versus just 3,300. This giant size meant the kidneys couldn't filter it out, and enzymes couldn't easily reach the GLP-1 part to destroy it.
The team made critical tweaks along the way. They modified the GLP-1 sequence to resist the DPP-4 enzyme. They used a special linker to connect the peptide to the Fc fragment. And they chose the IgG4 subtype specifically because it wouldn't accidentally trigger an immune attack. After years of engineering, the molecule — codenamed LY2189265 — was ready for human testing.
The Trials
The AWARD Program
Proving It Works in the Real World
Key moment
11 AWARD trials involving thousands of patients worldwide
Lilly launched one of the largest clinical trial programs ever for a diabetes drug. They called it AWARD — Assessment of Weekly Administration of dulaglutide in Diabetes. Across eleven major trials, thousands of patients tested dulaglutide against the leading diabetes treatments.
The results were consistently impressive. Dulaglutide matched or beat the competition in lowering blood sugar, while also helping patients lose weight. The once-weekly injection improved adherence dramatically — patients actually took their medicine.
On September 18, 2014, the FDA approved Trulicity. It came in a simple, pre-filled pen that patients could use at home without mixing or measuring. The injection took seconds. For many patients, it was the first time managing diabetes didn't feel like a full-time job.
The Crisis
The Heart Question
A Tense Wait for the REWIND Results
Key moment
REWIND: 12% reduction in heart events across 9,901 patients
After approval, a shadow hung over all GLP-1 drugs. The FDA required large cardiovascular safety trials — not to prove benefit, but to prove the drugs weren't secretly causing heart attacks. Several diabetes drugs had been pulled or restricted after unexpected heart risks surfaced years after approval.
The REWIND trial was massive: 9,901 patients across 24 countries, followed for over five years. Unlike other heart outcome trials that focused only on patients with existing heart disease, REWIND included many patients who simply had risk factors. This made the trial more challenging — it's harder to show benefit in healthier patients.
When the results dropped in June 2019, the room went silent, then erupted. Dulaglutide cut major cardiovascular events — heart attacks, strokes, and cardiovascular death — by 12%. And it worked even in patients who didn't already have heart disease. The drug designed for blood sugar was protecting hearts.
The Legacy
The Blockbuster Era
A $7 Billion Drug and Growing
Key moment
$7.4 billion in global sales in 2022
Trulicity became a juggernaut. By 2022, it was generating $7.4 billion in annual sales, making it one of the best-selling drugs in the world. Millions of patients in over 60 countries used it weekly.
But the GLP-1 landscape was shifting beneath Lilly's feet. Novo Nordisk's semaglutide (Ozempic, Wegovy) showed even greater weight loss, and Lilly's own tirzepatide (Mounjaro) — a dual GLP-1/GIP drug — was producing jaw-dropping results. Trulicity suddenly faced fierce competition from the very revolution it helped create.
Yet dulaglutide's legacy is secure. It proved that protein engineering could transform a fragile gut hormone into a once-weekly medicine. It showed that GLP-1 drugs could protect the heart. And for millions of patients, it was the drug that made diabetes manageable for the first time. The antibody shield had done its job.
Peptide history · 2005
Dulaglutide (Trulicity)
The Antibody Shield That Made Once-a-Week Possible
By fusing a gut hormone to an antibody fragment, Eli Lilly's engineers created a drug that lasts an entire week on a single injection — turning a daily burden into a Sunday morning routine for millions of people with diabetes.
Approved September 18, 2014
Single subcutaneous injection
Peptide fused to antibody fragment
Much larger than natural GLP-1
2022 global revenue
REWIND trial cardiovascular outcomes
Eli Lilly Research Team
The Protein Engineers · Eli Lilly and Company, Indianapolis
Lilly's scientists came up with a clever molecular design: fuse two copies of a modified GLP-1 to an antibody fragment called IgG4 Fc. This made the molecule large enough to avoid kidney filtration and long-lasting enough for once-weekly dosing. The resulting drug, codenamed LY2189265, became dulaglutide.
The challenge wasn't just making GLP-1 last longer — it was making a molecule that patients would actually want to use. Once a week changes everything.
Dr. Hertzel Gerstein
The Heart Protector · McMaster University / Population Health Research Institute
Led the landmark REWIND trial — a massive study of nearly 10,000 patients across 24 countries that proved dulaglutide didn't just control blood sugar, it actually protected the heart. The 2019 results showed a 12% reduction in major heart events, earning Trulicity an expanded FDA indication.
For the first time, we showed that a GLP-1 drug could reduce heart attacks and strokes even in patients who didn't already have heart disease.
Joel Habener, Svetlana Mojsov & Lotte Bjerre Knudsen
The Foundation Builders · MGH / Rockefeller University / Novo Nordisk
Their discovery of GLP-1 in the 1980s and the development of the first GLP-1 drugs created the scientific foundation that made dulaglutide possible. Every GLP-1 drug stands on their shoulders.
We proved GLP-1 could work. The next generation of scientists figured out how to make it work better.
12 milestones, 1987 – 2022.
- 1987GLP-1 discovered as a potent insulin-stimulating hormone from the gut
- 2005Exenatide (Byetta) approved — first GLP-1 drug, but requires twice-daily injection
- 2005Eli Lilly begins developing a GLP-1-Fc fusion protein (LY2189265)
- 2007Early clinical data shows the fusion approach extends action to one full week
- 2010Phase 2 trials published showing strong blood sugar control and weight loss
- 2011AWARD clinical trial program launches — 11 studies across the globe
- 2013REWIND cardiovascular outcomes trial begins enrolling nearly 10,000 patients
- 2014FDA approves Trulicity (dulaglutide) for type 2 diabetes on September 18
- 2016Trulicity available in over 40 countries worldwide
- 2019REWIND trial proves dulaglutide reduces heart attacks and strokes by 12%
- 2020FDA approves cardiovascular risk reduction indication
- 2022Trulicity reaches $7.4 billion in global annual sales
Think of GLP-1 as a tiny paper airplane that flies beautifully but gets crumpled up within minutes. Dulaglutide solves this by gluing the paper airplane to a heavy metal shield — an antibody fragment. Now it's too big for your kidneys to filter out, and too well-protected for enzymes to destroy. One injection lasts a whole week.
Molecular structure
- Type
- GLP-1-Fc Fusion
- Molecular Weight
- ~59,000 Da
- Half-life
- ~5 days
- Dosing
- Once Weekly
- Fc Fragment
- Modified IgG4
- DPP-4 Resistant
- Yes
2022 annual revenue
REWIND trial results
Worldwide availability
Across 24 countries
Real stories, real lives
David Kim
I was terrible at remembering daily medications. I'd miss doses all the time, and my blood sugar showed it. Switching to Trulicity was a game-changer. Every Sunday morning, one quick shot. That's it. My A1C dropped from 8.9 to 6.8 in six months. My doctor couldn't believe it.
Patricia Williams
After my heart scare, my doctor added Trulicity specifically because of the REWIND results. She said it would help my diabetes AND protect my heart. Two years later, my blood sugar is the best it's been in 15 years, I've lost 18 pounds, and my cardiologist is impressed with my numbers.
The future of Dulaglutide
- Higher Dose FormulationsApproved 2020
4.5 mg dose approved for patients needing stronger blood sugar control
- Combination TherapiesResearch
Testing dulaglutide with other diabetes drugs for even better results
- Kidney ProtectionClinical Trials
Studying whether GLP-1 drugs can slow kidney disease progression
- Next-Gen Fc FusionsResearch
New protein engineering approaches inspired by dulaglutide's design for other hormone drugs
Be inspired
The story of Dulaglutide is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.